Simplify Logo

Full-Time

Scientist II

In-Vivo Pharmacology

Confirmed live in the last 24 hours

Scorpion Therapeutics

Scorpion Therapeutics

51-200 employees

Develops precision oncology treatments for cancer

Biotechnology
Healthcare

Mid, Senior

Boston, MA, USA

Category
Lab & Research
Medical Research
Required Skills
Communications
Requirements
  • PhD. in pharmacology, biology or a related field
  • 2+ years of industry experience required
  • Experienced with cell culture and molecular biology techniques such as western blotting, qPCR and other plate-based assays and imaging techniques
  • Skilled in animal handling, compound formulation, dosing (PO/IV/SC/IP), basic surgery and necropsy techniques
  • Outstanding organizational, analytical and interpersonal skills
  • Ability to multi-task in a fast-paced environment while maintaining the highest quality of experimental execution/quality
  • Desire to contribute to teams working on challenging technical and scientific problems
  • A strong record of achievement, including publications
Responsibilities
  • Plan and coordinate in vivo experiments in-house and externally
  • Leverage organizational and communication skills to collaborate effectively with colleagues in biology and medicinal chemistry
  • Represent pharmacology on multiple project core teams
  • Analyze and present data to project teams and department meetings
  • Maintain high-quality, detailed experimental records within the ELN
  • Design and execute PK/PD/efficacy studies
Scorpion Therapeutics

Scorpion Therapeutics

View

Scorpion Therapeutics develops precision oncology treatments aimed at targeting specific cancer drivers. Their approach involves creating drugs that interact with validated cancer targets, enhancing their selectivity and safety to improve treatment outcomes. Unlike many competitors, Scorpion Therapeutics focuses on forming partnerships with larger pharmaceutical companies for the distribution of their drugs, allowing them to concentrate on research and development. Their goal is to provide effective cancer therapies that can be rapidly deployed to healthcare providers and patients worldwide.

Company Stage

Series A

Total Funding

$132.7M

Headquarters

Boston, Massachusetts

Founded

2020

Growth & Insights
Headcount

6 month growth

7%

1 year growth

11%

2 year growth

47%
Simplify Jobs

Simplify's Take

What believers are saying

  • Securing $150M in Series C funding and adding experienced leaders like Adam Friedman and Jeff Albers positions Scorpion for accelerated growth and innovation.
  • The company's world-class team and advisory boards enhance its capability to develop potentially best-in-class cancer treatments, as evidenced by promising preclinical data for STX-478 and STX-721.
  • Partnerships with major pharmaceutical companies provide financial stability and access to global markets, increasing the potential for successful drug commercialization.

What critics are saying

  • Frequent leadership changes, such as the recent CEO and CMO replacements, could lead to strategic instability and affect company morale.
  • The highly competitive oncology market requires continuous innovation to maintain a competitive edge, posing a risk if Scorpion fails to keep pace.

What makes Scorpion Therapeutics unique

  • Scorpion Therapeutics focuses on precision oncology, developing drugs that target specific cancer drivers, unlike broader-spectrum treatments offered by many competitors.
  • Their Precision Oncology 2.0 strategy aims to exceed traditional drug discovery methods in speed, efficiency, and quality, setting them apart in the biotech landscape.
  • Strategic partnerships with established pharmaceutical companies like Pierre Fabre allow Scorpion to leverage extensive distribution networks while focusing on R&D.